41 terminated. 41 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 41 | Terminated 41 |
Follow Anemia: new trials by email Literature Review of Anemia trials Research Report on Anemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| IRONICA: IRON Repletion In Heart Failure - A Comparison of Oral and IV Approaches Ferric Carboxymaltose, Ferrous Sulfate - Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF) | Phase 4 | Terminated | Syed Hamza Mufarrih | 42 | 2025-04-02 | 2026-07-20 |
| Effects of IV Iron Replacement on Exercise Capacity in Individuals With Heart Failure IV Iron Infusion Group - Heart Failure, Iron-deficiency | Phase 4 | Terminated | Radha Gopalan | 6 | 2024-01-24 | 2026-07-29 |
| Oral Iron Frequency for Childhood Restless Leg Syndrome/Periodic Limb Movement Disorder Ferrous sulfate - Sleep Disorder, Restless Legs Syndrome | Phase 4 | Terminated | Mayo Clinic | 6 | 2020-11-16 | 2024-05-22 |
| Daily Versus Alternate Day Iron Supplementation for the Treatment of Iron Deficiency Anemia in Pregnancy Ferrous sulfate - Pregnancy Related, Iron Deficiency Anemia of Pregnancy | Phase 4 | Terminated | The University of Texas Medical Branch, Galveston | 14 | 2020-10-27 | 2024-06-24 |
| Desmopressin for Bedwetting in Children With SCD Desmopressin - Nocturnal Enuresis, Anemia, Sickle Cell | Phase 4 | Terminated | Montefiore Medical Center | 8 | 2020-07-07 | 2024-05-07 |
| Study to Assess Feasibility and Safety of Iron Repletion With Feraheme in Iron Deficient Patients With Durable Ventricular Assist Device Support Ferumoxytol injection - Anemia | Phase 4 | Terminated | NYU Langone Health | 1 | 2020-01-15 | 2023-07-18 |
| ORal IrON Supplementation With Ferric Maltol in Patients With Heart Failure Carrying Left Ventricular Assist Devices Ferric maltol 30 mg (Feraccru®) - Heart Failure, Left Sided, Anemia, Iron Deficiency | Phase 4 | Terminated | Hannover Medical School | 11 | 2019-03-18 | 2020-04-21 |
| Assessing a Risk Model for G6PD Deficiency primaquine, chloroquine + primaquine - Malaria, Vivax, G6PD Deficiency | Phase 4 | Terminated | PATH | 54 | 2018-05-07 | 2021-11-12 |
| Frequent, Low-Dose Erythropoietin A Mechanistic Approach to Mitigate Adverse Cardiovascular Effects of Erythropoietin Low dose erythropoietin, High dose erythropoietin - Anemia, CKD | Phase 4 | Terminated | VA Office of Research and Development | 5 | 2017-11-02 | 2020-08-13 |
| A Double Blind Randomised Placebo-controlled Trial to Assess the Role of Iron Repletion in Glucose Homeostasis. Ferric Carboxymaltose, 0.9% sodium chloride solution - Iron-deficiency, Iron Toxicity | Phase 4 | Terminated | Prof Gérard WAEBER | 32 | 2017-06-21 | 2020-03-26 |
| Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other Anemias Deferiprone - Iron Overload, Sickle Cell Disease | Phase 4 | Terminated | ApoPharma | 134 | 2015-05-21 | 2024-01-10 |
| The Use of Iron Therapy for Patients With Anemia After Caesarean Section Ferinject, Ferrous fumarate, Placebo for ferrous fumarate - Postoperative Anaemia | Phase 4 | Terminated | Maastricht University Medical Center | 27 | 2015-03-02 | 2022-08-22 |
| Paricalcitol Improves Anemia of Inflammation Paricalcitol, Epoetin beta, Placebo - Anemia | Phase 4 | Terminated | Hospital Son Espases | 19 | 2014-12-01 | 2024-12-09 |
| Pre-operative Treatment With Erythropoietin and Iron Supplement in Cardiac Surgery Erythropoietin subcutaneously and Iron intravenously - Heart; Dysfunction Postoperative, Cardiac Surgery, Anemia, Iron-Deficiency | Phase 4 | Terminated | Catharina Ziekenhuis Eindhoven | 7 | 2014-08-01 | 2017-04-05 |
| Safety and Efficacy of Exjade in the Treatment of Transfusion-dependent Iron Overload in Aplastic Anemia Patients ICL670, Chelation, No chelation - Aplastic Anemia | Phase 4 | Terminated | Novartis Pharmaceuticals | 15 | 2014-06-23 | 2019-08-16 |
| Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other Anemias Deferiprone, Deferoxamine - Iron Overload, Sickle Cell Disease | Phase 4 | Terminated | ApoPharma | 230 | 2014-04-17 | 2021-08-10 |
| The Effect of Epogen and Venofer Dosing Management on Hemoglobin Stability Individualized Anemia Mangement Protocol - Anemia, End Stage Renal Disease | Phase 4 | Terminated | Michael Germain | 48 | 2013-07-01 | 2014-03-26 |
| Correcting Anemia and Native Vitamin D Supplementation in Kidney Transplant Recipients High Hb target, cholecalciferol - Kidney Transplantation, Anemia | Phase 4 | Terminated | CANDLE-KIT Trial Study Group | 161 | 2013-04-01 | 2019-02-04 |
| Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Patients Receiving Hemodialysis Peginesatide, Epoetin alfa - Anemia | Phase 4 | Terminated | Amgen | 41 | 2012-10-01 | 2014-04-21 |
| Intravenous Ferric Carboxymaltose (Ferinject) in Patients Undergoing Orthopaedic Surgery Ferinject 50 mg/ml, NaCl 0.9% - Anemia, Orthopedic Surgery | Phase 4 | Terminated | University Hospital Muenster | 3 | 2011-06-01 | 2013-08-09 |
Showing 20 of 41. Sign in to see all of them.
Anemia, Iron-Deficiency (9) · Anemia, Sickle Cell (6) · Kidney Failure, Chronic (6) · Renal Insufficiency, Chronic (6) · Heart Failure (3) · Iron Deficiencies (3) · Kidney Diseases (3) · Iron Overload (2) · Neoplasms (2) · Acquired Immunodeficiency Syndrome (1) · Anemia, Aplastic (1) · Atherosclerosis (1) · Bone Diseases, Metabolic (1) · Cardiovascular Diseases (1)
Hemic and Lymphatic Diseases (41) · Hematologic Diseases (40) · Metabolic Diseases (14) · Nutritional and Metabolic Diseases (14) · Iron Metabolism Disorders (12) · Urogenital Diseases (12) · Female Urogenital Diseases (11) · Female Urogenital Diseases and Pregnancy Complications (11) · Male Urogenital Diseases (11) · Pathological Conditions, Signs and Symptoms (11) · Urologic Diseases (11) · Anemia, Hypochromic (9) · Chronic Disease (9) · Disease Attributes (9)
Epoetin Alfa (8) · ferric carboxymaltose (8) · ferrous sulfate (5) · epoetin beta (4) · Erythropoietin (3) · Iron (3) · Deferiprone (2) · Ibuprofen (2) · Sodium Chloride (2) · continuous erythropoietin receptor activator (2) · ferryl iron (2) · Chelating Agents (1) · Chloroquine (1) · Cholecalciferol (1) · Contraceptives, Oral (1)
Hoffmann-La Roche (5) · Ortho Biotech Products, L.P. (3) · ApoPharma (2) · Amgen (1) · CANDLE-KIT Trial Study Group (1) · Catharina Ziekenhuis Eindhoven (1) · Children's Hospital Medical Center, Cincinnati (1) · Children's Hospital of Philadelphia (1) · Hannover Medical School (1) · Hospital Son Espases (1) · Indiana University (1) · Janssen Cilag S.A.S. (1) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (1) · London North West Healthcare NHS Trust (1) · Maastricht University Medical Center (1)
United States (17) · United Kingdom (4) · Germany (3) · Belgium (2) · Canada (2) · Egypt (2) · France (2) · Netherlands (2) · Saudi Arabia (2) · Spain (2) · Switzerland (2) · Venezuela (2) · Australia (1) · Brazil (1) · Greece (1)
Janet Kwiatkowski, MD (2) · Andrew Talal, MD (1) · Anna Maria van Eijk, MD PhD (1) · Arjunan Ganesh, MD (1) · Caroline Dore, BSc (1) · Charles T. Quinn, MD (1) · Gary Hoel, RPh, PhD (1) · Gavin Cho, MD (1) · Hugo K Van Aken, PhD, MD (1) · Jan Schmitto, Prof. MD (1)
PMID 36791280, PMID 17108343, PMID 21876446, PMID 27288381, PMID 30051186, PMID 30853478, PMID 32331365, PMID 34847228, PMID 35363499, PMID 35706490, PMID 35956390, PMID 36018224, PMID 37807937, PMID 38828109, PMID 39185895, PMID 39443013
2016 (1), I01CX001449 (1), U01DK071633 (1), U54HL070588 (1)